Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FKC288 in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
NCT05978661Phase 1Recruiting
- Sponsor
- Nanjing University School of Medicine
- Start
- Aug 2023
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FKC288 in systemic light chain amyloidosis, sponsored by Nanjing University School of Medicine. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 24 weeks. Started Aug 2023; status: recruiting.
02
Drugs
FKC288
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT05978661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978661.